Profusa Set to Generate First Commercial Revenue as Digital Health Platform Gains Global Traction
The Berkeley-based biosensor pioneer is set to secure its first service-based revenue while expanding its clinical footprint into the European vascular surgery market.
Investors and industry analysts often describe the transition from a research-phase entity to a revenue-generating commercial stage as the most treacherous “valley of death” for biotech firms. Profusa (NASDAQ: PFSA) appears to be navigating this crossing with calculated precision. The digital health company recently announced two major strategic wins that fundamentally shift its profile from a developer of promising technology to a commercial operator with revenue streams and international clinical adoption.
By launching its Lumee™ tissue oxygen monitoring platform into the global contract research organization (CRO) market, Profusa has effectively unlocked a door to a massive industry. This move targets a pharmaceutical services sector that experts value at $47.9 billion as of 2025. With a projected compound annual growth rate (CAGR) of 7%, this market could swell to over $91.2 billion by 2034. For Profusa, this represents the initiation of immediate, service-based revenue through research-use-only (RUO) offerings.
New Data Frontier for Drug Development
The pharmaceutical industry faces a constant, expensive battle against late-stage drug failure. Profusa’s Lumee system offers a potential solution by providing real-time, continuous biochemical data. Traditional assays often provide only a static snapshot of biological activity. In contrast, the Lumee sensors allow researchers to monitor tissue oxygenation dynamics in complex environments like tumor microenvironments or during wound healing processes.
To spearhead this commercial push, the company appointed Sean Givens as Head of Government and Healthcare Research Business. Givens, a veteran with two decades of experience in government contracting and drug development, sees the timing as ideal for the company’s evolution.
Givens stated:
“This is a natural and timely extension of Profusa’s platform building off of previous successes of this market. Our sensors are validated, ready to ship, and already generating strong interest across the industry. By partnering with CROs, we can help accelerate better drug development decisions while creating a meaningful, near-term revenue stream for Profusa.”
By integrating these sensors into CRO workflows, Profusa enables drug developers to access predictive biological data that was previously out of reach. This capability becomes particularly relevant as regulatory bodies increasingly favor new approach methodologies that reduce reliance on traditional animal models in favor of more predictive human-relevant data.
International Clinical Adoption in Vascular Surgery
While the CRO market represents a massive research opportunity, Profusa is simultaneously proving the clinical utility of its platform. The company recently added Dr. Theodosios Bisdas, a world-renowned vascular surgeon, to its growing customer base. Dr. Bisdas, who serves as the Head of Clinic of Vascular Surgery at the Athens Medical Center in Greece, will integrate Lumee Oxygen tissue monitoring into his daily practice and clinical studies.
This collaboration carries significant weight because of Dr. Bisdas’s standing in the medical community. As the founder of Vascupedia, a platform with over 10,000 users across 124 countries, his adoption serves as a powerful endorsement of the technology’s practical application in treating critical limb ischemia and diabetic foot complications.
Dr. Bisdas commented:
“Having used the Lumee Oxygen tissue monitoring in clinical trials, I look forward to integrating the technology in our practice at the Athens Medical Center. In addition, we will continue clinical evaluations of the platform for additional vascular applications where there is an unmet need. Based on my experience, the Lumee Oxygen tissue monitoring provides valuable treatment guidance and patient monitoring in both the inpatient and outpatient settings.”
Dr. Bisdas’s work will specifically focus on advancing the application of Lumee for home monitoring, a move that aligns with the broader healthcare trend toward hospital-at-home models. For patients with vascular disease, continuous monitoring can mean the difference between timely intervention and a catastrophic outcome like amputation.
Visionary Leadership and Scalable Growth
The dual-track strategy, capturing research revenue via CROs while building a clinical network with top-tier surgeons, highlights the versatility of Profusa’s underlying technology. The company’s injectable, long-lasting biosensors create a personalized biochemical signature that bridges the gap between personal wellness data and medical-grade clinical insights.
Ben Hwang, Ph.D., Profusa’s Chairman and CEO, views the addition of Dr. Bisdas as a cornerstone of the company’s expansion into the European market, stating:
“We welcome Dr. Bisdas to our roster of vascular surgeons as we continue to expand our network to now add the Vascular Surgery Clinic at the Athens Medical Center, Greece. We look forward to our collaboration with Dr. Bisdas as he integrates our Lumee Oxygen tissue monitoring to his practice as well as identifying opportunities for future clinical partnerships as we evaluate additional vascular applications of our platform technology.”
As Profusa scales, its success will likely depend on its ability to maintain this momentum. By securing immediate revenue through RUO kits and expanding its clinical influence through high-profile medical partnerships, the company is positioning itself as a central player in the next generation of continuous biochemical monitoring.
Read Next: Why Nvidia’s Tech Investments Could Transform the Entire AI Innovation Ecosystem
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $318,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
